- Home
- SNTI vs KRRO Comparison
SNTI vs KRRO Comparison
Compare SNTI & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | KRRO |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 58.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNTI | KRRO |
|---|---|---|
| Price | $1.05 | $8.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $9.00 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 4.6M | 322.3K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | $150.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $5.20 |
| 52 Week High | $5.10 | $55.89 |
Technical Indicators
Market Signals| Indicator | SNTI | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 35.10 |
| Support Level | $1.15 | $7.73 |
| Resistance Level | $1.28 | $8.59 |
| Average True Range (ATR) | 0.09 | 0.57 |
| MACD | -0.02 | 0.83 |
| Stochastic Oscillator | 1.19 | 39.10 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.